PAVM - PAVmed unit Lucid acquires certain licenses/assets to operate new lab for EsoGuard test

Lucid Diagnostics' (LUCD -4.7%) unit LucidDx Labs acquired certain licenses and other related assets from ResearchDx to operate its own new CLIA-certified, CAP-accredited clinical laboratory located in Lake Forest, California. Lucid — which is a majority-owned subsidiary of PAVmed (PAVM -5.4%) — said RDx had performed Lucid’s EsoGuard Esophageal DNA Test since its transfer from a university research laboratory and its commercial launch as a Laboratory Developed Test (LDT). "Having our own CLIA/CAP laboratory to perform EsoGuard testing will markedly streamline and simplify numerous important processes, including EsoGuard billing and collections. More fundamentally, it provides us with a strong, long-term, scalable infrastructure to accommodate accelerating growth in testing volume from our expanding EsoGuard commercialization activities.” EsoGuard is a DNA test for early detection of esophageal precancer in at-risk patients with gastroesophageal reflux disease. LucidDx and RDx also entered into a management services agreement under which RDx will continue to provide personnel and services to support the

For further details see:

PAVmed unit Lucid acquires certain licenses/assets to operate new lab for EsoGuard test